NCT05602675View on ClinicalTrials.gov

A Drug Interaction Study of LY3871801 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 2, 2022

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions
Healthy
Interventions
DRUG

LY3871801

Administered orally.

DRUG

Methotrexate

Administered orally.

DRUG

Warfarin

Administered orally.

DRUG

Dextromethorphan

Administered orally.

DRUG

Midazolam

Administered orally.

DRUG

Repaglinide

Administered orally.

Trial Locations (1)

75247

Covance Dallas, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY